Important Surgical and Clinical End Points in Neoadjuvant Immunotherapy Trials in Resectable NSCLC

Neoadjuvant immunotherapy may improve outcomes in patients with resectable NSCLC and is being evaluated in phase 2 and 3 studies. Nevertheless, preoperative treatment postpones resection; the potential for increased surgical complexity and greater intra- and postoperative morbidity and mortality is...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jay M., Kim, Anthony W., Marjanski, Tomasz, Falcoz, Pierre-Emmanuel, Tsuboi, Masahiro, Wu, Yi-Long, Sun, Shawn W., Gitlitz, Barbara J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8552106/
https://www.ncbi.nlm.nih.gov/pubmed/34746882
http://dx.doi.org/10.1016/j.jtocrr.2021.100221

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8552106/
https://www.ncbi.nlm.nih.gov/pubmed/34746882
http://dx.doi.org/10.1016/j.jtocrr.2021.100221

Ejemplares similares